Cas:1105576-13-3 N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide manufacturer & supplier

Chemical Name:N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide

CAS.NO:1105576-13-3

Synonyms:N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide

Molecular Formula:C₂₁H₁₉F₃N₂O₂S

Molecular Weight:420.4479696

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide Use and application,N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide technical grade,usp/ep/jp grade.

Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide manufacturer Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide supplier Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide vendor The mode of cooperation between domestic API companies and large international companies can lower the export threshold. N-[(1R,2R)-2-aMino-1,2-diphenylethyl]-4-(trifluoroMethyl)-BenzenesulfonaMide factory With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.